Tempus ECG-AF vs PMcardio
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your primary goal is to proactively identify elderly patients (65 or older) at increased risk of developing new-onset atrial fibrillation/flutter within the next 12 months. This tool is ideal for integrating into existing healthcare facility systems to support earlier identification and follow-up for at-risk individuals without a prior AF diagnosis or certain cardiac devices/procedures.
View Tempus ECG-AF →Choose PMcardio if…
Choose PMcardio if you need a rapid, comprehensive AI-powered ECG interpretation for over 50 cardiac conditions at the point of care, especially in emergency or primary care settings. This tool is well-suited for healthcare professionals seeking instant, expert-level ECG analysis, including critical diagnoses like STEMI/OMI and reduced LVEF, with visual AI explainability and mobile accessibility.
View PMcardio →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | PMcardio |
|---|---|---|
| Pricing | Contact vendor | Freemium |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | Mobile app (iOS and Android), Web platform, Enterprise integrations with EHR/CVIS and EMS systems |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | Pending AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
PMcardioPMcardio offers a mobile app and web platform, providing greater flexibility and accessibility for clinicians at the point of care. Tempus ECG-AF is a software solution integrated into existing healthcare facility systems, which may require more complex deployment and less direct user interaction. PMcardio's mobile app allows for instant AI-powered ECG interpretations by simply taking a picture of a 12-lead ECG, making it highly user-friendly for individual clinicians.
Clinical Value
PMcardioPMcardio detects over 50 cardiac conditions, including STEMI/OMI and reduced LVEF, and offers visual AI explainability with heatmaps (ECGxplainu2122), enhancing diagnostic confidence and serving as an educational tool. Tempus ECG-AF focuses specifically on identifying patients aged 65 or older at increased risk of developing atrial fibrillation/flutter within 12 months. While both are clinically validated, PMcardio's broader diagnostic scope and explainability features offer more comprehensive clinical utility.
Pricing & Value
PMcardioPMcardio offers a freemium model with 5 free ECG analyses per month and transparent pricing for its Pro Plan. Tempus ECG-AF requires contacting the vendor for pricing, although CMS reimbursement is available for certain CPT codes. The freemium model of PMcardio provides immediate value and allows users to experience the tool before committing to a paid plan, offering greater pricing transparency and flexibility.
Enterprise Readiness
TieBoth tools demonstrate enterprise readiness. Tempus ECG-AF is designed for integration into healthcare facility systems and is FDA-cleared, with CMS reimbursement available, indicating its suitability for large-scale deployment. PMcardio offers enterprise integrations with EHR/CVIS and EMS systems, along with dedicated plans for organizations, and is CE-certified. Both are HIPAA compliant and have BAAs in place. While Tempus has FDA clearance in the US, PMcardio is CE-certified in Europe and has FDA Breakthrough Device Designation, but is not yet FDA-cleared for clinical decision-making in the US.
Innovation
PMcardioPMcardio stands out with its 'Queen of Hearts' STEMI and OMI detection, 'LVsense' for reduced LVEF detection, and 'ECGxplain' for visual AI explainability with heatmaps, which provides transparency into the AI's decision-making. Tempus ECG-AF is innovative in its predictive capability for AF risk within 12 months. However, PMcardio's broader range of detected conditions and its unique explainability features represent a more comprehensive and advanced application of AI in ECG interpretation.
Support & Docs
PMcardioPMcardio provides a comprehensive 'Resources' section on its website, including a blog, regulatory information, security details, a help center, and an FAQ, indicating robust support and documentation. Tempus provides a transparency policy with contact information for their Customer Success Team and information on payment options. PMcardio's readily available and detailed online resources suggest a more extensive and accessible support system for users.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | PMcardio |
|---|---|---|
| Name | Tempus ECG-AF | PMcardio |
| Description | FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. | CE-certified AI platform that interprets ECGs to assess over 50 cardiac conditions rapidly and accurately. Clinically validated in more than 25 studies and trusted by over 100,000 clinicians, it delivers rapid, expert-level interpretations, empowering various healthcare professionals to act with confidence at the point of care. |
| Regulatory Clearance | FDA-cleared | CE-certified (Class IIb medical device under MDR), MHRA approved, ISO 13485, Tu00dcV certificates. |
| Primary Focus | Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months for patients 65 years or older. | Interprets ECGs to assess over 50 cardiac conditions, including STEMI/OMI, rhythms, reduced LVEF, and conduction disorders. |
| Key Features (Examples) | AI-based algorithm for 12-lead ECG analysis, detects signs associated with new onset Atrial Fibrillation (AF) within 12 months, intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. | Instant AI-powered ECG interpretations, detection of 50+ ECG findings (including STEMI/OMI, rhythms, reduced LVEF, conduction disorders), visual AI Explainability with heatmaps (ECGxplainu2122), automatic analysis of heart rate, axis, P wave, PR, QRS, and QT/QTc intervals. |
| Training Data | Trained on over 1.5 million ECGs from over 500,000 patients. | Trained on 4 million+ clinically labelled ECGs with matched patient outcomes. |
| Target Patient Population | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. | Not specified (intended for various healthcare professionals at the point of care). |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and PMcardio.
Frequently Asked Questions
More Comparisons
More matchups featuring Tempus ECG-AF or PMcardio
Backers
Who funded each tool's parent company.